IMNM (STOCKS)
Immunome, Inc.
$22.510000
-0.900000 (-3.84%)
Prev close: $23.410000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Clay B. Siegall
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,473.72M
- Employees
- 155
- P/E (TTM)
- -7.59
- P/B (TTM)
- 8.13
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
12
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.65 | $-0.59 | -0.0643 | -10.98% |
|
Jun 2025 (Q2)
|
$-0.50 | $-0.54 | +0.0395 | +7.32% |
|
Mar 2025 (Q1)
|
$-0.52 | $-0.69 | +0.1747 | +25.15% |
|
Dec 2024 (Q4)
|
$-1.28 | $-0.59 | -0.6896 | -116.80% |
Financial Statements
| Revenues | $9.68M |
| Benefits Costs and Expenses | $232.42M |
| Costs And Expenses | $232.42M |
| Operating Expenses | $243.90M |
| Research and Development | $174.41M |
| Other Operating Expenses | $69.50M |
| Operating Income/Loss | -$234.22M |
| Income/Loss From Continuing Operations After Tax | -$222.74M |
| Income/Loss From Continuing Operations Before Tax | -$222.74M |
| Interest Income/Expense After Provision For Losses | $11.48M |
| Interest Income/Expense Operating, Net | $11.48M |
| Net Income/Loss | -$222.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$222.74M |
| Net Income/Loss Available To Common Stockholders, Basic | -$222.74M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$2.96 |
| Diluted Earnings Per Share | -$2.96 |
| Basic Average Shares | 86,224,071 |
| Diluted Average Shares | 86,224,071 |
| Assets | $299.38M |
| Current Assets | $279.92M |
| Noncurrent Assets | $19.45M |
| Fixed Assets | $11.56M |
| Other Non-current Assets | $7.89M |
| Liabilities | $35.46M |
| Current Liabilities | $31.45M |
| Accounts Payable | $6.15M |
| Wages | $7.17M |
| Other Current Liabilities | $18.13M |
| Noncurrent Liabilities | $4.01M |
| Equity | $263.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $263.92M |
| Liabilities And Equity | $299.38M |
| Net Cash Flow From Operating Activities | -$185.03M |
| Net Cash Flow From Operating Activities, Continuing | -$185.03M |
| Net Cash Flow From Investing Activities | $74.56M |
| Net Cash Flow From Investing Activities, Continuing | $74.56M |
| Net Cash Flow From Financing Activities | $227.65M |
| Net Cash Flow From Financing Activities, Continuing | $227.65M |
| Net Cash Flow | $117.18M |
| Net Cash Flow, Continuing | $117.18M |
| Comprehensive Income/Loss | -$222.73M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$222.81M |
| Other Comprehensive Income/Loss | -$57.45M |